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ABSTRACT
This observational study describes the antimicrobial susceptibility testing (AST) methods and
interpretive criteria used in European hospitals during 2001, focusing specifically on detection of
methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Of 263
hospitals that took part in the ARPAC study, 192 submitted data on AST. Of these, 89% (n = 170)
routinely used a disk-diffusion AST method, 43% (n = 82) used a semi-automated method, and 70%
(n = 135) routinely determined MICs. Hospitals in southern Europe were less likely to use disk-
diffusion, but were more likely to use a semi-automated method (p <0.001). In total, 173 (90%)
interpreted AST results using CLSI breakpoints; 30% of these detected MRSA using unmodified CLSI
disk-diffusion methods, while 35% used the unmodified CLSI agar-screening method for MRSA; 41%
and 30% adhered to unmodified CLSI methodology for disk-diffusion and agar-screening, respectively,
to detect VRE. Some of the modifications made may have greatly reduced the ability of the tests to
detect MRSA ⁄VRE. For example, 20% of respondents used excessively high incubation temperatures
and 13% used inadequate incubation times to detect MRSA by disk-diffusion, and 28% used Mueller–
Hinton agar instead of brain–heart infusion agar in VRE screening plates. The majority of respondents
stated that they followed CLSI guidelines, but a high proportion had modified the CLSI methods for
detecting MRSA and VRE, which may compromise clinical management and antimicrobial resistance
surveillance.
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INTRODUCTION
The continuing emergence of pathogenic bacteria
that are resistant to first-line antibacterial agents
poses a challenge to clinical microbiology labor-
atories. Specifically, the choice of methods for
identifying resistant phenotypes and for measur-
ing resistance must be sufficiently robust to
provide a clinically relevant service. Secondary
to fulfilling this objective, laboratory methods
must keep abreast of developments in order to
enable more meaningful surveillance at all levels,
from monitoring resistance in one hospital over
time to tracking the epidemiology of resistance
both nationally and internationally.
Many organisations exist to provide antimicro-
bial susceptibility testing (AST) methods and
interpretative criteria. The organisation with the
greatest global recognition is probably the Clinical
and Laboratory Standards Institute (CLSI),
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formerly known as the National Committee for
Clinical Laboratory Standards (NCCLS) (http://
www.clsi.org). Most of the centralised European
antimicrobial resistance surveillance systems lis-
ted in a recent report [1] adhere to CLSI guide-
lines, and a large external quality assessment
exercise showed that CLSI guidelines are used
widely in Europe [2]. Some countries, including
the UK [3], France [4], Sweden [5] and Germany
[6], have developed their own national AST
guidelines, while others are based on CLSI meth-
ods and interpretative breakpoints.
The ARPAC (Antibiotic Resistance: Prevention
and Control) study was a Concerted Action,
funded by DG Research of the European Com-
mission, which aimed to lay the foundations for a
better understanding of the emergence and epi-
demiology of antimicrobial resistance in human
bacterial pathogens. The project was conducted
by four study groups of the European Society of
Clinical Microbiology and Infectious Diseases
(ESCMID). Data from European hospitals con-
cerning AST, antimicrobial resistance prevalence,
typing methods, antimicrobial consumption,
infection control policies and antibiotic prescri-
bing policies were collated and analysed. The
ESCMID Study Group for Antimicrobial Resist-
ance Surveillance (ESGARS) was responsible for
investigating the different AST methods and
interpretative criteria used across Europe during
2001. The findings of this investigation are the
subject of this article.
MATERIALS AND METHODS
Hospital recruitment
A recruitment flyer and initial screening questionnaire were
circulated during May 2002 to full members of ESCMID. In
total, 263 hospitals in Europe and Israel expressed an interest
in participating in the study. Hospitals in Israel were eligible
for inclusion because of a bilateral scientific cooperation
agreement for EC-funded studies. These 263 hospitals prov-
ided data on hospital characteristics for 2001, including
teaching status, total number of patient admissions, total
number of beds, and numbers of beds in surgical, medical and
intensive care unit (ICU) specialties. These data were com-
pared with data for the same characteristics from EU country-
specific datasets published by EUROSTAT, the Statistical
Office of the European Community (http://www.euro.
who.int), to assess the representativeness of the recruited
ARPAC sample.
Data collection
A detailed postal questionnaire was designed to capture AST
practices during 2001. The questionnaire, to be completed by a
medical microbiologist or another appropriate person, inclu-
ded general questions regarding AST, use of breakpoints,
participation in quality assurance in the respondent’s laborat-
ory, and the methods used for detection of specific resistance
phenotypes in Staphylococcus aureus and enterococci, including
methicillin-resistant S. aureus (MRSA) and vancomycin-resis-
tant enterococci (VRE). The questionnaire was developed,
piloted and revised by the ARPAC Steering Group before
being circulated to the 263 recruited hospitals during January
2003.
Statistical analysis
Data were entered into Microsoft Access 2000, and an
independent validation check was made on a 10% sample of
data entered. Statistical analysis was conducted using SPSS
v.12.0 for Windows (SPSS Inc., Chicago, IL, USA). Descriptive
analysis was conducted to identify associations between key
AST parameters and geographical and hospital factors, inclu-
ding hospital size, teaching status and case-mix variables.
Countries were classified into five European geographical
regions according to a standard reference system [7], modified
to place UK hospitals in western rather than northern Europe
(Table 1). Descriptive statistics were conducted using median
and inter-quartile range, and statistical testing was conducted
using non-parametric, Mann–Whitney U and Kruskal–Wallis
tests. Assessment of regional representativeness was estimated
using 2001 European bed data from EUROSTAT (http://
www.euro.who.int).
Table 1. Geographical location of
hospitals participating in ARPAC




n = 20 (10%)
Western Europe




n = 48 (25%)
South-eastern
Europe




n = 53 (28%)
Denmark (n = 5) Austria (n = 6) Bulgaria (n = 8) Bosnia (n = 2) Greece (n = 11)
The Netherlands (n = 8) Belgium (n = 21) Czech Republic (n = 3) Croatia (n = 5) Israel (n = 3)
Norway (n = 4) France (n = 6) Estonia (n = 2) Macedonia (n = 1) Italy (n = 10)
Sweden (n = 3) Germany (n = 11) Hungary (n = 10) Yugoslavia (n = 4) Malta (n = 1)
Switzerland (n = 5) Latvia (n = 2) Portugal (n = 3)
UK (n = 10) Lithuania (n = 3) Spain (n = 13)
Poland (n = 6) Turkey (n = 12)
Romania (n = 3)
Russia (n = 1)
Slovakia (n = 5)
Slovenia (n = 5)
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RESULTS
Response rate
Complete, useable responses concerning AST
during the year 2001 were received from 192
hospitals in 32 countries, representing 73% of the
hospitals recruited to the ARPAC study (Table 1).
The 192 hospitals that provided AST data were
more likely to have teaching status than hospitals
that failed to provide AST data (n = 71; p 0.02),
but there were no differences by geographical
region (p 0.13), hospital size (p 0.99), and pres-
ence or size of ICU (p 0.22).
Characteristics of participating hospitals
Total numbers of beds in hospitals recruited to the
ARPAC study were compared with published
numbers of hospital beds (acute and non-acute) for
2001 for each region. Estimated regional coverage
of acute-care beds ranged from 3% in western
Europe to 10% in northern Europe. Themajority of
participating hospitals that provided AST data
were teaching hospitals (146 ⁄ 192; 76%). Median
hospital size was 654 beds (inter-quartile range
407, 999), with eight hospitals failing to provide
bed data. Ninety-five percent of the hospitals
providing AST data had ICU beds, with a median
of 26 ICU beds (inter-quartile range 12, 45).
AST methods
Of the 192 responding hospitals, 89% (n = 170)
stated that they used a disk-diffusion AST
method routinely, with 43% (n = 82) using a
semi-automated method, and 70% (135) deter-
mining MICs routinely. Hospitals in southern
Europe were less likely to use disk-diffusion
(Table 2; p <0.01), and were more likely to use a
semi-automated method (Table 2; p 0.001) com-
pared with other regions. There was no associ-
ation between methods used and hospital size,
case-mix or teaching status. The reported man-
ufacturers of antimicrobial disks were Oxoid
(n = 95, 55.9%), Becton Dickinson (n = 71,
41.8%), Rosco (18.2%), Sanofi-Diagnostics Pas-
teur (14.7%) and bioMe´rieux (11.8%). MICs
were determined most frequently using Etest
strips (n = 119, 88.1%) and in-house broth
methods (n = 16, 11.9%). Of the 82 hospitals
that used a semi-automated system, 43.9%
(n = 36) used a Vitek system, 36.6% (n = 30)
used an ATB system, 9.8% (n = 8) used a
Walkaway system, and 2.4% (n = 2) used an
Autoscan system.
Breakpoints
Regardless of the AST methods used, 173 (90%) of
respondents stated that their laboratory inter-
preted AST results using breakpoints during 2001
(Table 2). In total, 171 hospitals specified which
organisation had set the breakpoints used. The
majority (n = 144, 84%), from 27 countries, used
breakpoints set by the CLSI. Other breakpoints
cited were generally set by national organisations.
Eleven (11%) hospitals used breakpoints set by
more than one organisation, generally CLSI and
national breakpoints. The majority of hospitals
(n = 169, 88%) routinely reported three AST
Table 2. Antimicrobial susceptibil-
ity testing methods used routinely
in 2001 in different European re-
gions Method used















Yes 19 (95) 52 (88) 47 (98) 12 (100) 40 (75) 170 (89)
No 1 (5) 7 (12) 1 (2) 0 (0) 13 (25) 22 (11)
Not stated 0 0 0 0 0 0
MIC 0.09
Yes 17 (85) 44 (75) 31 (65) 5 (42) 38 (72) 135 (70)
No 3 (15) 15 (25) 17 (35) 7 (58) 15 (28) 57 (30)
Not stated 0 0 0 0 0 0
Semi-automated 0.001
Yes 6 (30) 17 (29) 24 (50) 3 (25) 32 (60) 82 (43)
No 13 (65) 41 (69) 24 (50) 9 (75) 16 (30) 103 (54)




Yes 20 (100) 51 (86) 43 (90) 10 (83) 49 (93) 173 (90)
No 0 8 (14) 4 (8) 2 (17) 4 (7) 18 (9)
Not stated 0 0 1 (2) 0 0 1 (1)
aKruskal–Wallis test.
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categories, i.e., resistant, intermediate and sus-
ceptible.
Detection of MRSA
Participating hospitals supplied information
concerning the methods used to detect MRSA,
focusing on disk-diffusion testing and the agar-
screening method. In total, 126 hospitals provided
information concerning disk-diffusion methods
used to detect MRSA. Of these, 94 (75%) stated
that they used CLSI breakpoints to interpret AST
results, implying that they used CLSI disk-diffu-
sion methods, i.e., Mueller–Hinton agar plates
containing no added NaCl, incubated for a full
24 h at 33–35C, with either 5-lg methicillin disks
or 1-lg oxacillin disks [8,9]. Only 28 (30%) of the
94 hospitals followed all of these recommenda-
tions. The remaining hospitals used various com-
binations of the recommended test conditions
(Table 3).
Ninety-seven hospitals reported using MRSA
screening plates, with 72 (74%) using CLSI
methods and breakpoints. During 2000–2001, the
CLSI (NCCLS) expressed a preference for the use
of oxacillin rather than methicillin plates, but
supplied details for the use of both [8,9]. Thus, the
CLSI recommended use of Mueller–Hinton agar
supplemented with NaCl 4% w ⁄ v containing
either oxacillin 6 mg ⁄L or methicillin 10 mg ⁄L,
incubated for a full 24 h at 35C [8,9]. Twenty-five
(35%) of the 72 hospitals complied with all of
these recommendations. Again, various other
combinations of conditions were also used
(Table 3).
Detection of VRE
Ninety-six hospitals reported using disk-diffusion
methods to detect VRE, with 71 (74%) using CLSI
methods and breakpoints, while 49 reported
using vancomycin agar-screening plates, with 40
following CLSI guidelines. The CLSI state that
disk-diffusion should be performed on Mueller–
Hinton agar with 30-lg disks and incubation for
24 h at 35C, whereas the agar-screening method
should be carried out with brain–heart infusion
agar containing vancomycin 6 mg ⁄L, with incu-
bation for 24 h at 35C [8,9]. Only 41% (29 ⁄ 71)
and 30% (12 ⁄ 40) of hospitals adhered to the
complete CLSI methodology for disk-diffusion
and agar-screening, respectively. Table 4 gives
details for the hospitals that adhered to the
individual recommendations.
DISCUSSION
Despite the fact that a previous study concluded
that CLSI guidelines are followed widely in
Europe [2], it was not established at that time
Table 3. Disk-diffusion and agar-
screening methods used to detect
methicillin-resistant Staphylococcus
aureus (MRSA) in hospitals report-
ing use of CLSI guidelines
Method variable






Incubation temperature 33–35C 57 (61) 35C 42 (58)
Other (range 30–37C) 32 (34) Other (range 30–37C) 27 (38)
Not stated 5 (5) Not stated 3 (4)
Incubation time 24 h 55 (59) 24 h 36 (50)
Other (range 17–48 h) 34 (37) Other (range 17–72 h) 32 (44)
Not stated 5 (5) Not stated 4 (6)
Additional NaCl 0% 54 (57) 4% 39 (54)
Other (range 2–7.5%) 36 (38) Other (range 2–7.5%) 16 (22)







Methicillin 10 mg ⁄L
Oxacillin 6 mg ⁄L
0 (0)
50 (69)
Otherc 7 (7) Otherd 11 (15)
Not stated 8 (9) Not stated 11 (15)
Medium Mueller–Hinton agar 89 (95) Mueller–Hinton agar 53 (74)
Othere 2 (2) Otherf 15 (21)
Not stated 3 (3) Not stated 4 (6)
aSix hospitals used only methicillin disks, 85 used only oxacillin disks and three used both.
bOne hospital used only methicillin disks, 69 used only oxacillin disks and one used both.
cFour hospitals cited non-standard methicillin disk contents of 1–29 lg, and three cited non-standard oxacillin disk
contents of 5 lg.
dOne hospital used a non-standard methicillin concentration of 6 mg ⁄L and ten used non-standard oxacillin
concentrations of 1–5 mg ⁄L.
eOther media cited were IsoSensitest agar, Chapman agar and Natriomkloridplade agar.
fOther agar media cited were mannitol salt agar, ORSAB (Oxoid), nutrient agar + anoline, AES methistaph agar,
oxacillin screening agar (Becton Dickinson) and Chapman agar.
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whether claims made by laboratories were sub-
stantiated by the precise details of the specific
methods used in routine practice. The ARPAC
study found that, despite the majority of partici-
pating laboratories claiming to follow CLSI guide-
lines during 2001, >50% did not follow the
recommended methods for the detection of either
MRSA or VRE.
The present study is the first pan-European
study to assess detailed AST methodology used in
clinical microbiology laboratories. The strengths
of the study include the large sample of recruited
hospitals, the rigorous, piloted data collection
methods, and the high-quality data obtained from
participating hospitals. It is acknowledged that
hospitals were self-selecting, which increases the
risk of selection and response bias. Ideally, a full
listing of all acute-care hospitals in Europe would
provide a sampling frame for random selection of
eligible hospitals, but no such list exists. Hence
alternative, recognised approaches were used for
hospital recruitment [10].
In order to comply with the ARPAC data
collection strategy, questionnaires distributed
during January 2003 asked about AST methods
used during 2001. Thus, there was some potential
for recall bias. The response rate of 73% was high
within hospitals already willing to participate in
ARPAC, with no differences between responders
and non-responders, other than the finding that
teaching hospitals were more likely to return AST
data. However, these hospitals were a self-select-
ing, motivated sample willing to contribute data
to a collaborative research study. Despite this, the
data reveal significant inconsistencies when hos-
pitals claimed to follow the same AST guidelines.
In general, the ARPAC study confirmed that
European hospitals perform AST by disk-diffu-
sion methods in preference to MIC or (semi)-
automated methods [11]. However, when the data
were analysed by geographical region, it was
apparent that hospitals in southern Europe were
less likely to use disk-diffusion and more likely to
use a semi-automated method in comparison with
other regions. This aligns hospitals in southern
Europe more closely with clinical microbiology
laboratories in the USA that have determined
MICs and used automated instrument-based
methods in preference to the disk-diffusion test
for some time [12]. The major advantage of
automated AST is the efficiency gained in
setting-up and reading susceptibility results.
Overall, the performance of automated systems
correlates well with reference methods, but prob-
lems have been reported for some organism–
antimicrobial agent combinations, e.g., low-level
glycopeptide resistance in enterococci and sta-
phylococci [13]. A full understanding of the
limitations of an instrument, together with the
use of more appropriate supplementary testing
systems, is essential.
There is a growing move towards the surveil-
lance of antimicrobial resistance by collating AST
data generated routinely. Raw AST data must be
interpreted in order to provide meaningful results
for clinicians, and it is the interpreted data that
are used for surveillance. Interpretation is based
on the application of breakpoints, which are set
by various authorities, and which are notoriously
diverse [14]. Historically, this has made compar-
isons among laboratories difficult, especially at an
international level. However, more recently,
Table 4. Disk-diffusion and agar-
screening methods used to detect
vancomycin-resistant enterococci
(VRE) in hospitals reporting use of
CLSI guidelines
Method variable






Incubation temperature 35C 47 (66) 35C 32 (80)
Other (range 36–37C) 22 (31) Other (range 30–37C) 6 (15)
Not stated 2 (3) Not stated 2 (5)
Incubation time 24 h 48 (68) 24 h 24 (60)
Other (range 18–48 h) 21 (30) Other (range 17–72 h) 14 (35)




Other (range 5–6 lg)
58 (82)
7 (10)
Vancomyin 6 mg ⁄L
Other (range 4–30 mg ⁄L)
30 (75)
8 (20)
Not stated 6 (8) Not stated 2 (5)
Medium Mueller–Hinton agar 65 (92) Brain–heart infusion agar 14 (35)
Othera 5 (7) Otherb 21 (52)
Not stated 1 (1) Not stated 5 (12)
aOther media cited were IsoSensitest agar, Mueller–Hinton agar with blood, chocolate agar, brain–heart infusion
agar and ‘CNA’.
bOther media cited were bile-aesculine agar, aesculine ⁄ azide agar, Enterococcus el agar, Enterococcus agar (Difco),
VRE agar base (Oxoid) and Enterococcus screen agar (BB).
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greater numbers of individual laboratories have
opted to follow CLSI breakpoints [2], and two sets
of national guidelines have incorporated the CLSI
guidelines, or a modified version of CLSI guide-
lines [15]. The great majority of centralised
pan-European, international and pharmaceutical
surveillance systems listed in one report [1] use
CLSI guidelines, as do most laboratories in North
and South America. In the ARPAC study, 84% of
participating hospitals from 27 countries stated
that they used CLSI guidelines. In the European
Antimicrobial Resistance Surveillance System
(EARSS), 61% of participants from 19 countries
also stated that they used CLSI guidelines [2].
Widespread use of CLSI methods should provide
assurance that users are providing rigorous
results to clinicians and comparable AST
data, ensuring robust surveillance systems.
However, this assumption was not supported by
the ARPAC study, where detailed analysis
revealed considerable deviation from recommen-
ded practice.
A review of the literature reveals that alternat-
ive AST guidelines for MRSA detection include
numerous different media, salt concentrations,
incubation temperatures and incubation times.
All, or most, of the test conditions can be justified.
It is not so much the individual conditions that
are important, but rather the specific combina-
tions of conditions, and how they are used in
conjunction with specific breakpoints [16]. The
CLSI recommend that their breakpoints be used
only in conjunction with unmodified CLSI meth-
ods, and deviation from prescribed CLSI meth-
odology renders the CLSI breakpoints unusable.
This applies to any guidelines on methodology
and breakpoints. Thus, the two-thirds of ARPAC
participants who have modified the CLSI meth-
ods for detection of methicillin resistance in
S. aureus may be applying CLSI breakpoints
inappropriately.
Although the CLSI provides recommendations
for testing either oxacillin or methicillin to detect
methicillin resistance in S. aureus, it is recommend-
ed that oxacillin should be used in preference to
methicillin, as oxacillin is more resistant to de-
gradation in storage and is more likely to detect
heteroresistant isolates [17]. Historically, the rea-
son that many hospitals made the transition to
oxacillin may have been the discontinued pro-
duction of methicillin. More recently, it has been
suggested that cefoxitin may replace both meth-
icillin and oxacillin, as cefoxitin detects methicil-
lin resistance in S. aureus more reliably, and has
the added advantage that no special test condi-
tions are required [16].
Among the ARPAC participants, the disk-dif-
fusion test conditions most likely to be modified
were the incubation temperature and the incuba-
tion time. Although these modifications may be
perceived as minor, they are likely to have a
significant impact on AST results [18]. As well as
stating that disk-diffusion plates should be incu-
bated at 33–35C, the CLSI guidelines clearly state
that the incubation temperature must not exceed
35C for detection of MRSA. Despite this, 20% of
respondents used temperatures >35C, and 14%
used temperatures <33C (the latter is less
critical). Although 30C has been generally
quoted as being better able to detect heteroge-
neously resistant MRSA [19,20], the optimal incu-
bation temperature has also been reported to
depend on the combination of other test condi-
tions used, e.g., the antibiotic content of the disk
[21].
Although the majority of disk-diffusion tests
using CLSI methodology should be incubated for
16–18 h, the incubation time for MRSA detection
is a full 24 h. However, 13% of respondents
incubated tests for <24 h, and 22% for >24 h. A
period of 48 h rather than 24 h cannot be
assumed to be better for detection of MRSA,
e.g., Mouton et al. concluded specifically that
24 h is preferable [20]. The concentrations of
NaCl used by ARPAC participants also varied
considerably, and must be considered in con-
junction with intrinsically related test conditions.
The effect of changing the salt concentration
depends on the agar medium, inoculum size and
incubation temperature [16].
In general, test conditions for detection of VRE
are less complex and variable than those for
MRSA detection. Nevertheless, adherence to CLSI
guidelines was poor. Whereas 80% of respond-
ents used the recommended incubation tempera-
ture of 35C for agar-screening, only two-thirds
used this temperature for disk-diffusion tests.
Conversely, 60% of participants using the agar-
screening method, and 68% using disk-diffusion,
stated that they used the prescribed incubation
time of 24 h. The majority of laboratories devi-
ating from the recommendations incubated plates
for <24 h. This may be explained by the fact that
the CLSI recommends incubation for 16–18 h for
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the detection of most resistance phenotypes, and
some laboratories use this incubation period for
all AST. The few resistance phenotypes requiring
a longer incubation time do so for specific
reasons, and such phenotypes may not be
detected after incubation for 16–18 h. Thus, it is
critically important to follow the guidelines when
non-standard test conditions are justified and
recommended.
One of the biggest deviations from the CLSI
method for the detection of VRE was the use of an
agar other than brain–heart infusion agar for agar-
screening. Only 35% of respondents used this
agar, and 28% used Mueller–Hinton agar inap-
propriately. Although the original description of
the vancomycin screening test reported the use of
Mueller–Hinton agar, this was only a preliminary
study, which was stated to require further eval-
uation [22]. The original method was optimised
subsequently, and brain–heart infusion agar was
found to be superior to Mueller–Hinton agar [23].
Although the specificity and sensitivity of the two
agars were similar, there was a slight decrease in
sensitivity with Mueller–Hinton agar, depending
on the bacterial inoculum used. In addition,
results on brain–heart infusion agar were easier
to interpret, and the use of this agar in the
vancomycin screening test was consistent with
the enterococcal aminoglycoside screen test,
which also used brain–heart infusion agar; thus
its use was adopted by the CLSI [23].
In summary, the results of the pan-European
ARPAC study provided a valuable insight into
the characteristics of AST methods used by
selected hospitals from 32 countries. Despite the
fact that the majority of participants stated that
their laboratory used CLSI methods, the majority
of CLSI laboratories did not use the prescribed
methods to detect MRSA and VRE. No single set
of recommendations and test conditions can
detect every clinically relevant resistance pheno-
type [16], and this applies to CLSI methods as
well as to every other method [24]. However, as
demonstrated by the present study, many inap-
propriate modifications have been made to the
MRSA and VRE detection methods, thereby
compromising the ability of AST to detect these
highly important pathogens. Not only does this
hamper institutional and international compari-
sons of antimicrobial resistance trends, but it
impacts adversely on the clinical management
and outcome of individual patients. For these
reasons, standard methods should not be modi-
fied.
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